Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial
Toshinao Kawai, Mayumi Sako, Katsuhiro Arai, Takashi Ishikawa, Tomoko Toma, Taizo Wada, Yutaro Yada, Masataka Ishimura, Takehiko Doi, Satoshi Okada, Hiroshi Moritake, Kazushi Izawa, Masahiro Ueki, Eisuke Inoue, Hidefumi Nakamura, Masafumi Onodera · 2026
Read Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial by Toshinao Kawai, Mayumi Sako, Katsuhiro Arai, Takashi Ishikawa, Tomoko Toma, Taizo Wada, Yutaro Yada, Masataka Ishimura, Takehiko Doi, Satoshi Okada, Hiroshi Moritake, Kazushi Izawa, Masahiro Ueki, Eisuke Inoue, Hidefumi Nakamura, Masafumi Onodera (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289576.txt.
Description
Toshinao Kawai headed a 2026 randomized, blinded trial of thalidomide for bowel inflammation in chronic granulomatous disease. That rare immune defect, present in about 1 in 225,000 births, impairs germ killing and sparks excess inflammation. Nearly half of patients develop bowel disease with diarrhea, bleeding, pain, and fever, resembling classic inflammatory bowel disease in symptoms.
Patients aged one year or older received thalidomide or placebo under double-blind conditions for comparison. The abstract reports potential benefit with acceptable safety and no added infection risk signal in this first controlled trial of its kind. Standard options include steroids, immune suppressants, and biologics, all with trade-offs. A repurposed oral option would matter for families facing limited choices.
Catalog record
| CREATOR | Toshinao Kawai, Mayumi Sako, Katsuhiro Arai, Takashi Ishikawa, Tomoko Toma, Taizo Wada, Yutaro Yada, Masataka Ishimura, Takehiko Doi, Satoshi Okada, Hiroshi Moritake, Kazushi Izawa, Masahiro Ueki, Eisuke Inoue, Hidefumi Nakamura, Masafumi Onodera |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40996 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |